Saturday, 31 October 2026European Markets

EDP RENOVAVEIS And NEOEN Have A High Dividend Yield And Return On Equity In The Utilities Sector.

Loading stream...

(vianews) - edp renovaveis (edpr.ls) is among this list of stock assets with the highest dividend rate and return on equity on the utilities sector.

financial asset price forward dividend yield return on equity
edp renovaveis (edpr.ls) €19.35 0.46% 11.43%
neoen (neoen.pa) €28.44 0.44% 2.78%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. edp renovaveis (edpr.ls)

0.46% forward dividend yield and 11.43% return on equity

edp renováveis, s.a., a renewable energy company, plans, constructs, operates, and maintains electric power generation plants. the company operates wind and solar farms. as of december 31, 2021, it had an installed capacity of 5,908 megawatts in the united states; 2,194 megawatts in spain; 795 megawatts in brazil; and 1,142 megawatts in portugal. the company was incorporated in 2007 and is headquartered in madrid, spain. edp renováveis, s.a. operates as a subsidiary of edp-energias de portugal, s.a.

earnings per share

as for profitability, edp renovaveis has a trailing twelve months eps of €0.63.

pe ratio

edp renovaveis has a trailing twelve months price to earnings ratio of 30.71. meaning, the purchaser of the share is investing €30.71 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.43%.

yearly top and bottom value

edp renovaveis's stock is valued at €19.35 at 02:30 est, way under its 52-week high of €26.87 and above its 52-week low of €18.68.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, edp renovaveis's stock is considered to be overbought (>=80).

revenue growth

year-on-year quarterly revenue growth grew by 52.2%, now sitting on 2.08b for the twelve trailing months.

more news about edp renovaveis.

2. neoen (neoen.pa)

0.44% forward dividend yield and 2.78% return on equity

neoen s.a., an independent renewable energy production company, engages in the development and operation of renewable energy power plants. the company operates through solar power, wind power, storage, farm-down, development and investments, and eliminations segments. it operates in argentina, australia, canada, ecuador, the united states, finland, france, ireland, italy, jamaica, mexico, mozambique, portugal, el salvador, sweden, and zambia. neoen s.a. was incorporated in 2008 and is headquartered in paris, france. neoen s.a. operates as a subsidiary of impala sas.

earnings per share

as for profitability, neoen has a trailing twelve months eps of €0.34.

pe ratio

neoen has a trailing twelve months price to earnings ratio of 83.65. meaning, the purchaser of the share is investing €83.65 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.78%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, neoen's stock is considered to be overbought (>=80).

sales growth

neoen's sales growth is 63.4% for the ongoing quarter and 41.5% for the next.

yearly top and bottom value

neoen's stock is valued at €28.44 at 02:30 est, way under its 52-week high of €45.22 and way higher than its 52-week low of €25.72.

more news about neoen.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com